etoposide + ifosfamide + cisplatin + doxorubicin + bleomycin + vinblastine + dacarbazine

This is a multi-agent chemotherapy regimen composed of seven cytotoxic drugs: etoposide, ifosfamide, cisplatin, doxorubicin, bleomycin, vinblastine, and dacarbazine. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells through various pathways: - Etoposide inhibits topoisomerase II, leading to DNA strand breaks. - Ifosfamide is an alkylating agent that crosslinks DNA. - Cisplatin forms DNA adducts causing apoptosis. - Doxorubicin intercalates into DNA and inhibits topoisomerase II. - Bleomycin induces single and double-strand breaks in DNA via free radical formation. - Vinblastine disrupts microtubule assembly during mitosis. - Dacarbazine acts as an alkylating agent after metabolic activation. This combination does not correspond to a standard named regimen but includes drugs from regimens such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), VIP (etoposide, ifosfamide, cisplatin), and others used for lymphomas or germ cell tumors[1][2][3][4]. The rationale for combining these agents is to maximize antitumor efficacy by attacking cancer cells through multiple mechanisms while minimizing overlapping toxicities.